Thromboreductin Use In Pregnancy & Lactation

Pregnancy: There are no adequate data from the use of anagrelide in pregnant women. Studies in animals have shown reproductive toxicity (see Pharmacology: Toxicology: Preclinical safety data under Actions). The potential risk for humans is unknown and therefore, anagrelide is not recommended during pregnancy. If anagrelide is used during pregnancy, or if the patient becomes pregnant while using the medicinal product, she should be advised of the potential risk to the foetus.
Women of child-bearing potential: Women of child-bearing potential should use adequate birth control measures during treatment with anagrelide.
Breast-feeding: It is unknown whether anagrelide/metabolites transfer to human milk. Available data in animals have shown excretion of anagrelide/metabolites in milk. A risk to the newborn/infant cannot be excluded. Breast-feeding should be discontinued during treatment with anagrelide.
Fertility: No human data on the effect of anagrelide on fertility are available. In male rats, there was no effect on fertility or reproductive performance with anagrelide. In female rats, using doses in excess of the therapeutic range, anagrelide disrupted implantation (see Pharmacology: Toxicology: Preclinical safety data under Actions).